PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
PROTHENA CORP PUBLIC LTD CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.48+0.13 (+1.56%)
Close on Oct 19, 2026
- Market cap
- $442.19M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.44 (−14.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PROTHENA CORP PUBLIC LTD CO grew revenue 427.3% to $54.53M over the twelve months to Jun 30, 2026.
Revenue
$54.53M
+427.3% vs. a year earlier
Operating income
-$55.51M
TTM Q2 2026
EPS, diluted
-$0.84
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $442.19M
- P/E ratio
- –
- Price to sales
- 8.11
- Price to book
- 1.54
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $54.53M
- Net income
- -$43.99M
- EPS, diluted
- -$0.84
- Book value per share
- $5.50
- Diluted shares
- 52M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$54.53M+427.3% YoY
Operating income
-$55.51M
Net income
-$43.99M
EPS, diluted
-$0.84
Reported periodTrailing twelve months